NCT00223301View on ClinicalTrials.gov

Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Multiple Sclerosis
Interventions
DRUG

Mycophenolate Mofetil (cellcept)

Trial Locations (1)

75390-8806

University of Texas Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

Biogen

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT00223301 - Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter